Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer

NCT05245474 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

186

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Rectal Cancer

Interventions

COMBINATION_PRODUCT: Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)

Sponsor

Beijing Friendship Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]